Answers are grounded in this paper and cite their sources.
Ozanezumab (GSK1223249) is a humanised, Fc-disabled, monoclonal antibody (mAb) which targets the amino terminus of Neurite Outgrowth Inhibitor A (Nogo-A) which is currently being developed for the treatment of amyotrophic lateral sclerosis (ALS).
No takes yet. Share an insight, caveat, or question.
Lynch et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: